Brand Name(s):Evista
Indication:Secondary prevention of osteoporotic fractures in postmenopausal women
Rationale:
Considered:Oct-07
Review Date:Jul-23
Comments:
See Formulary
…………………………
NICE CG164 can be found at:http://www.nice.org.uk/nicemedia/live/14188/64202/64202.pdf
Issued: June 2013
…………………………
Raloxifene is recommended as an alternative treatment option for the secondary prevention of osteoporotic fragility fractures in postmenopausal women:
* who are unable to comply with the special instructions for the administration of alendronate and either risedronate or etidronate, or have a contraindication to or are intolerant of alendronate and either risedronate or etidronate
and
* who also have a combination of T-score, age and number of independent clinical risk factors for fracture as indicated in the table within the guidance
NICE TA 161
Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended January 2010)
October 2008